The long read sequencing market in North America is expected to grow from US$ 570.24 million in 2021 to US$ 2,254.97 million by 2028; it is estimated to grow at a CAGR of 21.7% from 2021 to 2028. Five years ago, genomic sequencing was restricted to the research environment. At present, it is increasingly used in clinical practice, and over the next five years, genomic data from over 60 million patients are expected to be generated within healthcare. Genomic sequencing is rapidly transitioning into clinical practice, and implementation into healthcare systems has been supported by substantial government investment, totaling over US$ 4 billion in at least 14 countries. These national genomic-medicine initiatives drive transformative change under real-life conditions while addressing barriers to implementation and gathering evidence for broader adoption, thereby driving the market growth.
The List of Companies
- Bionano Genomics
- F. HOFFMANN-LA ROCHE LTD.
- Illumina, Inc.
- Oxford Nanopore Technologies
- Pacific Biosciences of California, Inc.
- PerkinElmer, Inc.
- Quantapore, Inc.
By Technology
- Single-Molecule Real-Time Sequencing
- Nanopore Sequencing
- Loop Genomics Long Read Sequencing
By Product
- Instruments
- Consumables
- Services
By Application
- Identification and fine mapping of structural variation
- Tandem Repeat Sequencing
- Pseudogene discrimination
- Resolving allele phasing
- Reproductive genomics
- Cancer
- Viral and Microbial Sequencing
By Workflow
- Pre-sequencing
- Sequencing
- Data Analysis
By End User
- Academic Research Institutes
- Hospitals and Clinics
- Pharma and Biotechnology Companies
Market Overview
North America dominates the global long-read sequencing market, driven primarily by the U.S., with Canada as a secondary contributor. This leadership stems from rising demand from biopharmaceutical and biotechnology sectors for advanced genomic tools, coupled with robust R&D investments from academic and research institutions. The region’s growth is further propelled by government and private-sector initiatives promoting precision medicine, alongside significant funding for genomic studies. The COVID-19 pandemic amplified this momentum, as long-read sequencing became critical for tracking viral mutations and informing public health strategies.
Key Growth Drivers
-
Healthcare Innovation: Adoption of cutting-edge genomic technologies in diagnostics and therapeutics.
-
Precision Medicine Initiatives: Federal and private programs accelerating personalized healthcare solutions.
-
Funding Surge: Increased grants for genomic research (e.g., Genome Canada’s $40M COVID Genomics Network).
-
Pandemic Impact: Scalable sequencing infrastructure developed during COVID-19, with initiatives like the U.S. ramping up variant surveillance (sequencing 3% of cases via GISAID) and partnerships such as Pacific Biosciences-Labcorp’s SARS-CoV-2 genome sequencing.
Strategic Insights for Stakeholders
-
Leverage Data-Driven Opportunities:
-
Invest in analytics to identify underserved niches (e.g., rare disease research, agricultural genomics).
-
Develop tailored solutions for biopharma, such as long-read sequencing for complex gene synthesis or structural variant detection.
-
-
Collaborate for Competitive Edge:
-
Forge partnerships with academic hubs and public health agencies to align with emerging research needs.
-
Explore cross-sector alliances (e.g., tech firms for AI-driven genomic analysis) to enhance sequencing accuracy and speed.
-
-
Capitalize on Post-Pandemic Trends:
-
Expand infectious disease surveillance capabilities, anticipating demand for rapid pathogen sequencing.
-
Highlight long-read sequencing’s advantages (e.g., comprehensive variant detection, haplotype resolution) in marketing strategies.
-
-
Navigate Regional Dynamics:
-
In the U.S., target federal funding channels (NIH, CDC) and biotech clusters (Boston, San Francisco).
-
In Canada, align with Genome Canada’s networks and prioritize public-private genomic projects.
-
-
Future-Proof Investments:
-
Monitor regulatory shifts favoring precision medicine and direct-to-consumer genetic testing.
-
Anticipate demand for portable sequencing technologies (e.g., nanopore platforms) in decentralized healthcare settings.
-
Conclusion
The North American long-read sequencing market offers sustained growth, fueled by technological adoption and pandemic-driven innovation. Stakeholders must prioritize strategic collaborations, niche market penetration, and agile responses to public health needs. By aligning with regional funding priorities and emphasizing the technology’s unique benefits—such as resolving complex genomic regions—companies can secure a competitive advantage in this rapidly evolving landscape.
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
Author’s Bio:
Suryakant Gadekar
Senior Market Research Expert at Business Market Insights
